http://www.feuxdelamour.com/v4/index.php?action=history&feed=atom&title=The_Way_To_Make_Money_With_Succimer 2026-06-28T18:34:23Z Historique pour cette page sur le wiki MediaWiki 1.20alpha http://www.feuxdelamour.com/v4/index.php?title=The_Way_To_Make_Money_With_Succimer&diff=73076&oldid=prev 2017-02-27T12:57:56Z

<p>Page créée avec « Mean age at diagnosis among BRCA [http://www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar).html www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar)... »</p> <p><b>Nouvelle page</b></p><div>Mean age at diagnosis among BRCA [http://www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar).html www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar).html] mutation carriers is reported to range from 45 to 48 years old in the literature [14, 16]. In our series, median age at diagnosis was 54 years old both for sporadic and for HBOC ovarian cancer. HBOC ovarian tumours are generally diagnosed at a higher stage and grade as compared to sporadic cancers [1, 4]. On the contrary, in our study, a significant higher proportion of patients in the BRCA+ group was diagnosed at stage II when compared to the sporadic group. Furthermore, HBOC ovarian tumours are typically of serous histology [1, 2, 16] Generally, among HBOC ovarian cancers, no borderline or mucinous cancers are reported [4]. Consistent with the literature, in the present series, most of the HBOC ovarian tumours (70%) were high-grade serous and 25% were undifferentiated tumours. On the contrary, among the sporadic tumours, only around 50% of tumours were high-grade serous and endometrioid; clear cells, and mucinous tumours were observed as well. In our series, radical primary surgery was performed in more than 70% of patients in both groups. In one-third of the patients, both in BRCA+ and in control groups, a neoadjuvant chemotherapy was administered. In our series, in patients who underwent surgery after neoadjuvant chemotherapy, optimal cytoreduction [http://www.selleckchem.com/products/cb-839.html CB-839 solubility dmso] was achieved in all BRCA+ and in 70% of controls. According to many studies, patients carrying BRCA mutation have a higher response rate to platinum-based chemotherapy [https://en.wikipedia.org/wiki/Succimer Succimer] [2, 5, 6, 7, 9, 10, 17]. In the study of Cass et al., a significantly greater response to first-line platinum-based chemotherapy and a longer disease-free interval was observed among patients with BRCA+ ovarian cancer [5]. Also, in the study of Tan et al., in BRCA+ patients, a significantly higher response rate to first-, second-, and third-line platinum-based chemotherapy as compared to controls was observed [10]. In the study of Gorodnova et al., complete clinical response was documented in 34% of BRCA mutation carriers versus 4% of non-carriers (p</div>

Cloth59butter